Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP-700 dose optimization with anesthetic premedications in healthy adults
NL-OMON25663Phase 1Recruiting
- Sponsor
- The Medicines Company
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of moxetomidate, sponsored by The Medicines Company. Primary endpoints: Safety and tolerability and Pharmacodynamic-driven dose optimization. Started May 2015; status: recruiting.
02
Drugs
moxetomidate
Beyond the preview
Go deeper on NL-OMON25663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25663.